🔗 Share this article The Global Health Body Issues Concern Over Severe Shortage of Obesity Injections Less than a tenth of individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, caution the global health agency as it releases its initial advice on the therapies. With more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication. Based on projections, over two billion are projected to be obese by 2030 unless action is taken. "The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization. GLP-1 Therapy Shortage Even under the current best projected scenario, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, per the health organization. The recommendation urges countries and companies to widen availability, by strategies like voluntary licensing. A patent on semaglutide – the core component of a leading brand – is due to expire in several countries in 2026. How Weight-Loss Jabs Work GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of commencing the weekly injections. Studies points to patients may regain a significant portion a year later of halting the drug, because their typical food cravings resume. To be overweight or obese increases your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
Less than a tenth of individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, caution the global health agency as it releases its initial advice on the therapies. With more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication. Based on projections, over two billion are projected to be obese by 2030 unless action is taken. "The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization. GLP-1 Therapy Shortage Even under the current best projected scenario, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, per the health organization. The recommendation urges countries and companies to widen availability, by strategies like voluntary licensing. A patent on semaglutide – the core component of a leading brand – is due to expire in several countries in 2026. How Weight-Loss Jabs Work GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of commencing the weekly injections. Studies points to patients may regain a significant portion a year later of halting the drug, because their typical food cravings resume. To be overweight or obese increases your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Excess weight affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the WHO.